ORIC Pharmaceuticals, Inc. (ORIC)
$11.99-0.33%Close
SELLBEAR · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.2B
- Beta
- 0.99
- P/E (TTM)
- -8.87
- Short % float
- 33.50%
- Days to cover
- 9.8
- SI change
- -6.9%
- 1W
- -1.80%
- 1M
- -0.66%
- vs SPY 1W
- -2.96%
- vs SPY 1M
- -3.66%
Industry peers
FMP comparable companies · ranked by market cap
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.84+0.86%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.90+1.01%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 17$16.55+0.53%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.60-0.15%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 12$18.15-0.59%
- CRVSSELLCorvus Pharmaceuticals, Inc.$845MCRISISQ 13$10.05+3.04%
- AVBPSELLArriVent BioPharma, Inc.$767MCRISISQ -5$16.46+0.12%
- VSTMBUYVerastem, Inc.$725MRECOVERYQ 4$8.25+3.33%
- NVCTSELLNuvectis Pharma, Inc.$523MCRISISQ 39$19.69+4.92%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ORIC?
- LOPJLB’s latest quantitative signal on ORIC Pharmaceuticals, Inc. (ORIC) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ORIC in?
- ORIC Pharmaceuticals, Inc. (ORIC) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does ORIC Pharmaceuticals, Inc. (ORIC) do?
- ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another cand…